253 related articles for article (PubMed ID: 25661017)
1. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
Modi A; Siris ES; Tang J; Sen S
Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
[TBL] [Abstract][Full Text] [Related]
2. Cost and consequences of noncompliance to oral bisphosphonate treatment.
Eisenberg DF; Placzek H; Gu T; Krishna A; Tulsi BB
J Manag Care Spec Pharm; 2015 Jan; 21(1):56-65. PubMed ID: 25562773
[TBL] [Abstract][Full Text] [Related]
3. Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries.
Kjellberg J; Jorgensen AD; Vestergaard P; Ibsen R; Gerstoft F; Modi A
Osteoporos Int; 2016 Dec; 27(12):3535-3541. PubMed ID: 27394414
[TBL] [Abstract][Full Text] [Related]
4. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
5. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
[TBL] [Abstract][Full Text] [Related]
6. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
8. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
Sato M; Ye W; Sugihara T; Isaka Y
BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
[TBL] [Abstract][Full Text] [Related]
9. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
[TBL] [Abstract][Full Text] [Related]
11. Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients.
Zhao Y; Johnston SS; Smith DM; McMorrow D; Krohn K; Krege J
Osteoporos Int; 2013 Sep; 24(9):2525-33. PubMed ID: 23529293
[TBL] [Abstract][Full Text] [Related]
12. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
Olsen KR; Hansen C; Abrahamsen B
Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
[TBL] [Abstract][Full Text] [Related]
13. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
Modi A; Tang J; Sen S; Díez-Pérez A
Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
[TBL] [Abstract][Full Text] [Related]
14. Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Siris ES; Modi A; Tang J; Gandhi S; Sen S
Curr Med Res Opin; 2014 Jan; 30(1):123-30. PubMed ID: 24102262
[TBL] [Abstract][Full Text] [Related]
15. Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy.
Viswanathan HN; Curtis JR; Yu J; White J; Stolshek BS; Merinar C; Balasubramanian A; Kallich JD; Adams JL; Wade SW
Appl Health Econ Health Policy; 2012 May; 10(3):163-73. PubMed ID: 22510025
[TBL] [Abstract][Full Text] [Related]
16. Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.
Ward MA; Xu Y; Viswanathan HN; Stolshek BS; Clay B; Adams JL; Kallich JD; Fine S; Saag KG
Osteoporos Int; 2013 Apr; 24(4):1195-206. PubMed ID: 23100119
[TBL] [Abstract][Full Text] [Related]
17. Real-world clinical and economic outcomes for daily teriparatide patients in Japan.
Burge R; Sato M; Sugihara T
J Bone Miner Metab; 2016 Nov; 34(6):692-702. PubMed ID: 26661475
[TBL] [Abstract][Full Text] [Related]
18. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men.
Mikyas Y; Agodoa I; Yurgin N
Appl Health Econ Health Policy; 2014 Jun; 12(3):267-77. PubMed ID: 24477429
[TBL] [Abstract][Full Text] [Related]
20. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]